Cite
HARVARD Citation
Yap, Y. et al. (n.d.). 40OBiomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). Annals of oncology. p. . [Online].